Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P11509

UPID:
CP2A6_HUMAN

ALTERNATIVE NAMES:
1,4-cineole 2-exo-monooxygenase; CYPIIA6; Coumarin 7-hydroxylase; Cytochrome P450 IIA3; Cytochrome P450(I)

ALTERNATIVE UPACC:
P11509; A7YAE5; B2R7F6; P00190; P10890; Q16803; Q4VAT9; Q4VAU0; Q4VAU1; Q9H1Z7; Q9UCU0; Q9UK48

BACKGROUND:
Cytochrome P450 2A6, also referred to as CYPIIA6 and Cytochrome P450 IIA3, is integral to the body's ability to process both pharmaceuticals and carcinogens. It possesses low phenacetin O-deethylation activity but is highly active in the hydroxylation of specific anti-cancer medications and the metabolic activation of aflatoxin B1, a known carcinogen. This enzyme's activity underscores its importance in pharmacokinetics and toxicology.

THERAPEUTIC SIGNIFICANCE:
The exploration of Cytochrome P450 2A6's functions offers a promising avenue for the development of novel therapeutic approaches. By leveraging its enzymatic activities, there is potential to optimize drug dosing, minimize adverse effects, and prevent drug-induced toxicities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.